Effect of Ad-p16 Combined with CDDP or As_2O_3 on Human Bladder Cancer Cells

Summary:To evaluate the therapeutic efficiency of combined use of p16-expressing adenovirus andchemotherapeutic agents CDDP or As_2O_3 on human bladder cancer cell line EJ,the human bladdercancer cell line EJ were transfected with adenovirus-mediated p16 gene(Ad-p16),with administra-tion of cisplatin(CDDP)or arsenic trioxide(As_2O_3).The cell growth,morphological changes,cellcycle,apoptosis and molecular changes were measured using cell counting,reverse microscopy,flowcytometry,cloning formation,immunocytochemical assays and in vivo therapy experiments to evalu-ate the therapeutic efficacy of such combined regimen.Ad-p16 transfer and CDDP or As_2O_3 adminis-tration to EJ cells could exert substantially stronger therapeutic effects than the single agent treat-ment.Especially in in vivo experiments,combined administration of p16 and CDDP or As_1o_3 inducedalmost tumor diminish compared to the partial tumor diminish induced by single agent.Moreover,delivery of Ad-p16,or administration of minimal-dose CDDP     

p53重组腺病毒联合增殖细胞核抗原反义寡核苷酸治疗膀胱癌的研究

目的：探讨重组腺病毒p53(Ad-p53)与增殖细胞核抗原反义寡核苷酸（PCNA-ASO）联合应用对膀胱癌的抑瘤效应。方法：用腺病毒将p53{感染强度（MOI）100}导入细胞，PCNA-ASO(1.6μmol/L)在脂质体（Lipofectin）介导下转染细胞，通过噻唑蓝比色法（MTT）、流式细胞术、克隆形成、建立移植瘤模型，探讨其体内外抗瘤活性。结果：Ad-p53与PCNA-ASO联合应用明显抑膀胱癌胞EJ(89.3%)和BIU-87(78.6%)生长，细胞克隆形成能力分别下降74.8％和67.5％，S期比率（EJ细胞11.4％，BIU-87细胞14.6％）明显降低，细胞生长受阻于G1期(EJ细胞62.2％，BIU-87细胞56.8％)；联合应用7d后，肿瘤体积较初始分别下降47.6％和36.4％。结论：Ad-p53联合PCNA-ASO可抑制膀胱癌细胞体内外生长，产生协同效应。     

培养医务人员信息素养的途径

就如何加强医务人员信息素养培养进行论述,包括信息素养基本涵义、概况及信息素养培养的途径与措施。     

膀胱移行细胞癌中p53突变、bcl-2和PCNA表达的临床意义

To correlate the frequency of p53 mutations, bcl-2 expression and the proliferation status (proliferating cell nuclear antigen, PCNA) in patients with bladder cancer with cell proliferation, apoptosis and their clinico-pathologic findings. Paraffin-embedded sections from 39 superficial (T1G1-G3) and 23 invasive (T2-T4a G3 N0M0) primary transitional cell carcinomas (TCC) in the bladder were investigated immunohistochemically for p53, bcl-2 and PCNA. The median follow-up was 37 months; 24 had recurrences. The proliferation index (PI) was expressed as a percentage of the PCNA-positive cells in the tumor cells. Apoptosis was detected by terminal deoxy-nucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL), and the apoptotic index (AI) was expressed as a percentage of the TUNEL-positive tumor cells. p53 mutation was identified in 50 patients (80.6%). The mutation was most common in tumors grade 3 (91.3%) as compared to grade 2 (78.5%) and grade 1 (72.7%, P<0.05). Stage pT2 tumors had a higher frequency of p53 mutation (95.7%) as compared to pTa-1 tumors (74.3%, P<0.01). Only 14 tumors (22.5%) expressed bcl-2; grade 3 tumors expressed bcl-2 significantly more frequently (P<0.05); there was no correlation between bcl-2 and tumor stage. There was no interrelation between p53 mutation and bcl-2 expression (P>0.05). The PI ranged from 17.2% to 41.8% (median 22.4%) and the AI from 1.9% to 3.5% (median 2.9%) in bladder cancer. Statistical analyses revealed a close associations between PI, AI and tumor grade and stage of bladder cancer. p53 mutation correlates with invasion. p53 and PCNA overexpression may offer valuable additional prognostic information in bladder tumors. With the progression of the tumor grade, cell proliferation may be accompanied by frequent apoptosis in bladder cancer, but the PI increased much more than the AI.     

膀胱移行细胞癌中p53突变、bcl-2和PCNA表达的临床意义(英文)

目的探讨膀胱癌中 bcl-2、p53、PCNA 表达与细胞增殖、凋亡和临床病理学参数之间的关系。方法 SABC 免疫组化分折62例(T1G1-G339例,T2-T4aG3 NOM023例)甲醛固定和石蜡包埋的膀胱癌标本 bcl-2、p53和 PCNA 蛋白的免疫反应性。平均随访37个月,24例复发。增殖指数(PI)表示肿瘤细胞中 PCNA 阳性细胞百分比。TUNEL 法检测细胞凋亡,凋亡指数(AI)表示肿瘤细胞中凋亡细胞的百分比。结果 62例膀胱癌中,50例(80.0%)发生 p53突变,与 G1(72.7%)和 G2(78.5%)相比较 G3(91.3%)更多见(P<0.05);pT2期(95.7%)p53突变率较 pTa-1期(74.3%)高(P<0.01)。14例(22.5%)发现有 bcl-2表达,bcl-2表达阳性率 G3明显高于 G1和 G2(P<0.05),与分期无关(P>0.05)。Bcl-2表达与 p53突变无关。在膀胱癌中,PI 为17.2%～41.8%(平均为22.4%),AI 为1.9%～3.5%(平均为2.9%)。统计分析显示 PI 与肿瘤分级、分期关系密切,AI 与肿瘤的分级有明显关系。结论结果表明,p53突变与浸润性行为呈正相关。在膀胱癌中 p53和 PCNA 过表达可能能提供有价值的预后信息。随着肿瘤的进展,肿瘤细胞过度增殖可能伴有频繁的凋亡,但增殖指数的增加明显强于凋亡指数的增加。     

ShRNA沉默基因DNA甲基转移酶3b的表达对膀胱癌T24细胞增殖的影响

目的体外研究重组质粒pshRNA-DNMT3b对膀胱癌T24细胞中DNMT3bmRNA和蛋白的沉默效应以及细胞增殖抑制的影响，初步探讨DNMT3b在膀胱肿瘤发生过程中的作用。方法实验分为空白对照组、HK组及pshRNA-DNMT3b组（24、48、72h）；常规培养T24细胞，用脂质体lipofectamine2000将重组质粒pshRNA-DNMT3b转染进入T24细胞，后进行RT．PCR、WesternBlot、MTY检测，观察pshRNA-DNMT3b对T24细胞中DNMT3bmRNA、蛋白质水平变化以及细胞增殖的影响。结果重组质粒pshRNA-DNMT3b成功的转染进入T24细胞；RT-PCR电泳结果用Gel-proanalyzer图像分析系统进行灰度分析，空白对照组、HK组、pshRNA-DNMT3b组（24、48、72h）条带的IOD相对比值（DNMT3／β-actin）分别是（99．56±1．24）％、（99．12±1．35）％、（75．77±1．42）％、（44．69±1．05）％和（20．52±0．89）％；Westernblot图像分析结果各组的相对比值分别是（99．43±1．28）％、（98．90±1．31）％、（67．83±1．02）％、（43．43±1．05）％和（21．92±0．89）％；在MTF检测中空白对照组和HK组之间差异无统计学意义（P〉0．05），pshRNA-DNMT3b组仅在72h后和前2组之间差异有统计学意义（P〈0．01），但抑制率仅增加0．45％左右。结论重组质粒pshRNA-DNMT3b能有效的降低膀胱癌1、24细胞中基因DNMT3bmRNA的转录及蛋白的表达，但在抑制细胞增殖上作用甚微。     

社区健康管理在老年2型糖尿病控制中的应用效果

[目的]探寻老年2型糖尿病患者适宜的社区健康管理模式。[方法]选取社区老年2型糖尿病患者60人,随机分为干预组和对照组,每组各30人。通过采取健康教育、情志调理、饮食和运动量化管理、指导患者合理用药和健康监测等措施,对为期9个月的干预效果进行评价。[结果]干预组患者在糖尿病知识知晓率、糖代谢指标及生活质量评分方面较干预前明显改善并优于对照组(P<0.01,P<0.05)。[结论]社区健康管理模式能改善社区老年2型糖尿病患者的血糖控制效果,提高其生活质量。     

肾周间隙在重症急性胰腺炎中的螺旋CT表现

重症急性胰腺炎（severe acute pancreatitis,SAP）是迄今为止一种临床常见的并发症多、病死率高,治疗棘手的急腹症。其主要致病机制为各种原因所致的胰管阻塞,导致胰酶释放进入间质组织,产生自溶性的脂肪坏死和非特异性的胰腺及胰周组织炎症。胰脾是腹膜后器官,居于腹膜后间隙的肾旁前间隙内。SAP早期往往在胰腺周围形成急性积液,并且向胰外远处区域扩散,病变在肾旁前间隙内向上、下及双侧扩散,累及肾前、后筋膜及锥侧筋膜,     

老年人等密度硬膜下血肿的CT诊断

老年人等密度硬膜下血肿大部分为慢性硬膜下血肿,也包括部分亚急性硬膜下血肿和少数急性硬膜下血肿。本文回顾性分析了我院自1996年以来经手术钻孔引流证实的病例共47例。